CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques

Jin Fan; Hua Liang; Xiaolin Ji; Shuo Wang; Jing Xue; Dan Li; Hong Peng; Chuan Qin; Cassian Yee; Yiming Shao

doi:10.1038/s41467-019-09725-6

Nature Communications (May 2019)

CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques

Jin Fan,
Hua Liang,
Xiaolin Ji,
Shuo Wang,
Jing Xue,
Dan Li,
Hong Peng,
Chuan Qin,
Cassian Yee,
Yiming Shao

Affiliations

Jin Fan: Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center
Hua Liang: State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases
Xiaolin Ji: State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases
Shuo Wang: State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases
Jing Xue: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College
Dan Li: State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases
Hong Peng: State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases
Chuan Qin: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College
Cassian Yee: Department of Melanoma Medical Oncology, Department of Immunology, UT MD Anderson Cancer Center
Yiming Shao: Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center

DOI: https://doi.org/10.1038/s41467-019-09725-6
Journal volume & issue: Vol. 10, no. 1
pp. 1 – 9

Abstract

Read online

Viral rebound following discontinuation of antiretroviral therapy (ART) is a major obstacle for HIV cure. Here, the authors show that adoptive cellular therapy using autologous Env-specific T cells augmented by therapeutic vaccination can control viral rebound after ART interruption in a SHIV macaque model.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal